Hello, I’m Dr Jonathan Abbas. I’m the director of the acute leukemia and blood cancer program with Tennessee Oncology in Nashville, Tennessee. I specialize in hematologic malignancies, specifically acute leukemia, and my center treats over a hundred patients a year with aggressive chemotherapy for AML many of whom have sAML, including t-AML and AML-MRC.
Today I’m going to talk about improving outcomes in patients with sAML subtypes, t-AML and AML-MRC, using VYXEOS.
An important challenge in treating AML is recognizing that sAML is a unique entity, which behaves very differently than conventional AML. Because we now have some novel treatments for sAML, it is imperative that we identify these patients to be able to give them a chance at remission. Therefore, whenever I identify an sAML patient who is a candidate for induction therapy, I always ask myself, is this patient a good candidate for VYXEOS?
Patients with sAML have historically exhibited poor survival, so selection of appropriate first-line therapy is important to achieving remission and ultimately prolonging survival.
In patients who are clinically stable and able to tolerate intensive chemotherapy, considering a treatment such as VYXEOS may improve outcomes in patients with sAML.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION